Recent RWE study shows Johnson & Johnson COVID-19 vaccine results in long-lasting protection
- Researchers utilised national claims, laboratory, and hospital data covering 168 million individuals to conduct a matched case-control study between January 1 and September 7, 2021 for 17 million fully vaccinated individuals matched on calendar time, 3-digit zip code, age, sex, and comorbidity scores.
- A single shot of the Johnson & Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalisations, and intensive care unit (ICU) admissions
- “We continue to undertake extensive efforts to study the durability of protection offered by the Johnson & Johnson vaccine amidst the ever-changing COVID-19 pandemic,”
Mathai Mammen, M.D., Ph.D., Executive Vice President, Pharmaceuticals, Janssen Research & Development LLC, Johnson & Johnson
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.